Importance

Loading Importance Indicators...

Abstract

The present invention relates to a racemic or enantiomerically enriched O-carbamoyl-phenylalaninol compound represented by the following structural formula V and pharmaceutically acceptable salts thereof to treat diseases of the central nervous system: ##STR1## wherein Ph is a phenyl group as described as follows: ##STR2## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, R.sup.1 and R.sup.2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cyclic propyl and 5 to 7-membered aliphatic cyclic compounds, and R.sup.1 and R.sup.2 may be joined to form a 5 to 7-membered cyclic compound which may comprise zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, or zero to one oxygen atom directly unconnected, excluding the instance where R, R.sup.1, and R.sup.2 are all hydrogen, and the pharmaceutically acceptable salts thereof. The present invention also relates to O-carbamoyl-(D)-phenylalaninol compounds, represented by the following structural formula IX: ##STR3## wherein Ph, R.sup.1, and R.sup.2 are as described above, and the pharmaceutically acceptable salts thereof.

Loading the Abstract Image...

First Claim